Status:
RECRUITING
Fexofenadine in Patients With Active Rheumatoid Arthritis
Lead Sponsor:
October 6 University
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
PHASE2
Brief Summary
Rheumatoid arthritis (RA) is an inflammatory autoimmune polyarthritis affecting ∼1% of the world population, resulting in the loss of joint function and progressive structural damage in affected joint...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Moderate to severe RA (disease activity score-28 joints: DAS-28 \> 3.2) were recruited.
- Age between 18 - 60 years having active disease according to the diagnosis of an experienced rheumatologist, being under treatment with disease-modifying anti-rheumatic drugs (DMARDs), not receiving cytokine inhibitors
- Signing informed consent and willingness of the participant to accept randomization to any assigned treatment arm.
- Exclusion Criteria:
- History of biological DMARDS.
- History/presence of acute heart disease, liver and kidney diseases, COPD
- Intolerance or allergy to fexofenadine or methotrexate
- Alcohol abuse
- Any changes in using medication (changing the dosage or type of medicines
- Receive hormone replacement therapy, warfarin, and other anticoagulants
Exclusion
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05264025
Start Date
June 1 2022
End Date
January 1 2026
Last Update
July 31 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Beni-Suef Hospital
Banī Suwayf, Egypt
2
Faculty of Medicine - Beni Suef Hospital
Banī Suwayf, Egypt